Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922839 | 0.82 | TSHR (0.47) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL7638659 | 0.81 | TSHR (0.59) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL14576606 | 0.80 | TDP1 (0.39) | TSHRALDH1A1TDP1 | |
| SCHEMBL4331907 | 0.80 | TSHR (0.76) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL537361 | 0.80 | TSHR (0.53) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL5698745 | 0.80 | TSHR (0.75) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL24562 | 0.80 | TSHR (1.00) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL1782287 | 0.80 | TSHR (0.49) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL536923 | 0.79 | TSHR (0.52) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL160208 | 0.79 | TSHR (0.73) | TSHRALDH1A1THRBPOLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833865-B1 | CROSS-LINKABLE, SILANE-MODIFIED COPOLYMERS | WACKER CHEMIE AG (DE) | 2010-03-17 | — | — | EP | claimed |
| US-20080145676-A1 | free radical copolymerization of a vinyl ester or acrylate monomer with a post-crosslinkable ethylenically unsaturated silane such as methacryloyloxymethylmethoxydimethylsilane; aqueous dispersion or water-redispersible powders; high storage stability with rapid cure; adhesive, cements, binder, coating | WACKER CHEMIE AG (DE) | 2008-06-19 | — | — | US | claimed |
| US-6841694-B2 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2005-01-11 | — | — | US | claimed |
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| CN-109803826-B | Laminate and method for producing same | 信越化学工业株式会社 | 2021-05-11 | — | — | CN | disclosed |
| CN-108472685-B | Method for producing laminate | 信越化学工业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| CN-111533854-A | Silicon modified acrylic resin and application thereof | 上海亿祺化工技术有限公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3045506-B1 | ACTINIC ENERGY RADIATION-CURABLE ACRYLIC SILICONE RESIN COMPOSITION AND COATED ARTICLE | SHINETSU CHEMICAL CO (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-20190291394-A1 | LAMINATED BODY AND PRODUCTION METHOD THEREFOR | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-09-26 | — | — | US | disclosed |
| EP-3527366-A1 | LAMINATED BODY AND PRODUCTION METHOD THEREFOR | Shin-Etsu Chemical Co., Ltd. (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-10196409-B2 | Organosilicon compound and curable composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-3210988-B1 | ORGANOSILICON COMPOUND AND CURABLE COMPOSITION | SHINETSU CHEMICAL CO (JP) | 2018-06-20 | — | — | EP | disclosed |
| EP-1713822-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006072407-A1 | REACTIVE SILICIC ACID SUSPENSIONS | WACKER CHEMIE AG (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072411-A1 | CROSS-LINKABLE, SILANE-MODIFIED COPOLYMERS | WACKER CHEMIE AG (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005073216-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| US-6841694-B2 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-6815554-B2 | REACTING A HALOALKYLSILANE WITH A SALT OF AN UNSATURATED CARBOXYLIC ACID IN THE PRESENCE OF A PHASE TRANSFER CATALYST; BONDING AGENTS | WACKER-CHEMIE GMBH (DE) | 2004-11-09 | — | — | US | disclosed |
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| US-20020151736-A1 | PROCESS FOR PREPARING UNSATURATED ORGANOSILICON COMPOUNDS | WACKER-CHEMIE GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | ELOVL1, ELOVL6, DEGS1 | TSHR 4650/4885ALDH1A1 402/4885THRB 4533/4885 |
| US-10196409-B2 | Organosilicon compound and curable composition | MASTL, PIEZO1, MCM6 | TSHR 3198/4885ALDH1A1 1875/4885THRB 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.